What Does Methadone Come Up As in a Drug Test?

Methadone shows up as “methadone” on a drug test, not as a generic opiate. Unlike heroin, codeine, or morphine, which typically trigger the “opiates” line on a standard immunoassay panel, methadone is a synthetic opioid with a distinct chemical structure that most opiate screens do not detect at all. If a test is looking for methadone, it uses a dedicated methadone-specific panel, and the result will be labeled accordingly. This distinction surprises many people, and the details around which tests catch it, what they actually measure, and what can throw off the results are worth understanding.

Why Methadone Does Not Show Up on a Standard Opiate Panel

A basic five-panel drug test, the kind used for most pre-employment screenings in the United States, checks for amphetamines, cannabinoids, cocaine, opiates, and phencyclidine (PCP). The “opiates” category on that panel is designed to detect natural and semi-synthetic opioids derived from the opium poppy, primarily morphine and codeine. Heroin metabolizes into morphine, so it triggers that same line. But methadone is fully synthetic. Its molecular shape is different enough that it does not cross-react with the antibodies used in a standard opiate immunoassay.

This means you could be taking methadone daily and pass a standard five-panel drug test with a clean result for opiates. The test simply is not built to recognize methadone. To detect it, the testing laboratory or employer must specifically request a methadone panel, sometimes listed as “MTD” or “EDDP” on requisition forms. Extended panels, such as a ten-panel or twelve-panel test, often include methadone alongside other synthetic opioids like oxycodone and fentanyl, but this is not guaranteed. The specific drugs on an extended panel vary by employer, clinic, or program.

What the Test Actually Measures

When a drug test does include a methadone-specific panel, it usually targets one of two things: methadone itself or its primary urinary metabolite, EDDP (2-ethylidene-1,5-dimethyl-3,3-diphenylpyrrolidine). Many modern immunoassays prefer to detect EDDP rather than the parent drug, because EDDP is consistently excreted in urine regardless of urine pH. Methadone excretion, by contrast, can vary with how acidic or alkaline your urine is, which means a test targeting only the parent drug might miss someone who is actually taking it.

An evaluation of one widely used EDDP enzyme immunoassay found that at a cutoff of 150 ng/mL, the test had perfect sensitivity and a specificity above 98%, with overall agreement with confirmatory lab methods exceeding 99%.¹ In that study, every specimen that screened positive was confirmed by a more precise lab technique, and no specimen that screened negative turned out to contain the metabolite. That is unusually clean performance for an immunoassay, which is partly why EDDP-based tests have become the preferred screening method in many methadone maintenance programs.

The common cutoff concentrations are 150 ng/mL and 300 ng/mL. At the lower cutoff, the test catches more true positives and has slightly higher specificity. At 300 ng/mL, specificity drops a small amount but remains above 95%.¹ Which cutoff a lab uses depends on the purpose of the test: compliance monitoring in a clinic may favor the lower cutoff to confirm patients are actually taking their prescribed medication, while forensic or workplace testing may use the higher one to reduce the chance of a disputed result.

Screening Versus Confirmation

Any positive result on an immunoassay screen is considered presumptive. It tells the lab “something that looks like methadone or EDDP is present,” but immunoassays work by antibody binding, and antibodies are not perfectly selective. A positive screen is always followed, in any legitimate testing protocol, by a confirmation test using a different technology. The gold standard for confirmation is gas chromatography-mass spectrometry (GC/MS) or liquid chromatography-tandem mass spectrometry (LC-MS/MS). These instruments physically separate and identify molecules by their mass and fragmentation patterns, which means they can distinguish methadone from anything else that might have tricked the initial screen.

This two-step process matters because it protects both directions. A false positive on the screen gets caught and corrected at confirmation. And a true positive that looked ambiguous on the screen gets definitively confirmed. If you receive a positive result and were not taking methadone, you have the right to request confirmatory testing, and any accredited lab should have already performed it before reporting a final positive.

What Can Cause a False Positive for Methadone

False positives on methadone immunoassays are uncommon but do happen, and the causes are specific enough to be worth knowing. The most well-documented culprit in recent years is vortioxetine, an antidepressant sold under the brand name Trintellix (formerly Brintellix). In one investigation, urine specimens from seven patients taking normal doses of vortioxetine tested positive for methadone on one particular immunoassay platform (the Roche MDN2 assay) but came back negative on GC/MS confirmation and on two other immunoassay platforms.² The issue was traced to a vortioxetine metabolite that cross-reacted with the antibodies in that specific assay. Because vortioxetine is metabolized extensively and the cross-reactive metabolite builds up in the body, patients taking the drug could test falsely positive even when the parent drug was undetectable in their urine.

This is platform-specific. The false positive appeared on one manufacturer’s assay but not others, which is a reminder that “a drug test” is not one universal technology. Different labs use different assay kits, and those kits have different antibody formulations with different cross-reactivity profiles. If you are taking vortioxetine and are subject to regular methadone testing, your prescriber or the testing lab should be aware of this interaction. Other medications have occasionally been reported to cause cross-reactivity on methadone screens, including certain antihistamines and some antipsychotics, but the evidence is more scattered and less systematically studied than the vortioxetine finding.

How Long Methadone Stays Detectable

Methadone has a notably long half-life compared to most opioids, averaging somewhere around 24 to 36 hours in most adults, though it can range from 8 to 59 hours depending on individual metabolism. This long half-life is part of why it works well for opioid maintenance therapy: a single daily dose can maintain stable blood levels and prevent withdrawal. But it also means the drug and its metabolites linger in the body longer than short-acting opioids like heroin or oxycodone.

In urine, methadone and EDDP are generally detectable for roughly 2 to 7 days after the last dose in someone taking it regularly. For a single or occasional dose, the window is shorter, often closer to 1 to 3 days. These ranges are rough because individual variation is enormous, driven by factors like liver enzyme activity, body fat (methadone is lipophilic and accumulates in fatty tissue), urine concentration, and the specific cutoff the lab uses.

Oral fluid (saliva) testing detects methadone over a somewhat shorter window, typically 1 to 3 days, because it reflects more recent drug exposure. Blood testing is even more time-limited, mainly useful for determining whether someone is currently under the influence rather than whether they used the drug recently. Hair testing extends the window dramatically, potentially detecting methadone use for 90 days or more, since drug molecules become incorporated into the hair shaft as it grows.

Different Specimen Types and What They Tell You

The choice of specimen type is not just about convenience. Each type answers a slightly different question, and methadone programs, courts, employers, and forensic investigators choose accordingly.

Urine: The most common specimen for routine drug testing. It is non-invasive, well-studied, and has established cutoffs and confirmation methods. EDDP-based urine immunoassays are the workhorse of methadone compliance monitoring.
Oral fluid: Increasingly used in workplace and roadside testing because collection is observed and harder to tamper with. Methadone concentrations in saliva correlate reasonably well with blood levels, making oral fluid a decent proxy for recent use.
Blood or serum: Used in clinical settings to measure actual blood concentrations for dosing adjustments, or in forensic settings after overdose or death. Post-mortem blood methadone concentrations can overlap with levels seen in living patients on maintenance therapy, which complicates interpretation in death investigations.³
Hair: Used when a longer detection window is needed, such as in child custody cases or monitoring programs where monthly or quarterly testing is preferred. A hair sample can capture a three-month history of use in a single test.

In forensic and post-mortem contexts, interpreting blood methadone levels is tricky. One large analysis of methadone-related deaths found that blood concentrations in fatal cases overlapped with therapeutic ranges seen in living patients on maintenance, meaning a high methadone blood level alone does not prove the drug was the cause of death.³ Deaths involving methadone alone tended to have higher concentrations than deaths involving multiple substances, but the overlap in ranges means toxicologists must weigh the whole clinical picture rather than relying on a single number.

Why the Same Dose Can Produce Different Test Results in Different People

Methadone is primarily broken down in the liver by a set of enzymes, with CYP2B6 playing a particularly important role. The gene that codes for this enzyme is highly variable across the population. Some people carry genetic variants that make their version of CYP2B6 less active, which means they metabolize methadone more slowly, leading to higher blood levels from the same dose. Others have a more active form and clear the drug faster.

Research has shown that carriers of the CYP2B6*6 variant have significantly lower conversion of methadone to EDDP compared to people with the standard version of the gene.⁴ In practical terms, this means a slow metabolizer might have more methadone and less EDDP in their system after the same dose. For a urine test that targets EDDP rather than the parent drug, a slow metabolizer could theoretically produce a weaker positive or, in edge cases, a negative result despite genuinely taking the medication. This is one reason some programs test for both methadone and EDDP together, to reduce the chance of a false negative due to metabolic variation.

The CYP2B6*6 variant is not rare. It is found in a substantial percentage of people across many populations, which means this is not an exotic edge case. For anyone on methadone maintenance who gets unexpected or fluctuating test results, genetic variation in drug metabolism is a plausible explanation worth discussing with a provider.

Testing in Pregnancy and Newborns

Methadone maintenance during pregnancy is one of the established treatments for opioid use disorder in expectant mothers, and drug testing in this context involves some unique specimen types. In addition to standard urine and blood testing of the mother, clinicians and researchers can test meconium (a newborn’s first stool), umbilical cord tissue, placental tissue, and even neonatal hair to assess prenatal drug exposure.

A study comparing these matrices found that hair samples from the mother were the most sensitive for detecting methadone exposure during pregnancy, identifying 11 positive cases out of the group studied. Meconium identified 9, while placental and umbilical cord samples each identified 6.⁵ The differences matter because each specimen type covers a different window of pregnancy. Meconium accumulates starting around the second trimester, so it captures a longer exposure history. Umbilical cord and placental tissue reflect more recent exposure near delivery. Hair, depending on its length, can reflect the entire pregnancy.

Testing in this population is not about punishment. It is about clinical decision-making: a newborn exposed to methadone in utero needs monitoring for neonatal abstinence syndrome, and knowing the extent and timing of exposure helps neonatologists prepare. The choice of which specimen to test depends on what question the clinician needs answered and what specimens are practically available.

Methadone Versus Other Synthetic Opioids on Drug Panels

The situation with methadone is part of a broader pattern in drug testing. As synthetic opioids have become more common, the old “opiates” panel has become increasingly inadequate. Fentanyl, for example, also does not show up on a standard opiate screen, nor does tramadol, buprenorphine, or oxycodone (though some newer opiate panels do cross-react with oxycodone to varying degrees). Each of these drugs requires its own specific immunoassay or, at minimum, an extended panel that explicitly includes it.

This means that a person who tests “negative for opiates” could still be actively using fentanyl, methadone, or several other synthetic opioids. The five-panel test was designed decades ago when heroin and codeine were the primary opioid concerns, and it has not kept up with the drug landscape. Extended panels with 10 to 16 targets are becoming more common in clinical and forensic settings, but they are more expensive and not universally adopted in workplace testing. If you are being tested and want to know whether methadone is on the panel, you can ask the testing facility or your employer what specific drugs the panel covers. This information is not always volunteered, but it is not confidential.

Compliance Monitoring and the “Proving You Are Taking It” Problem

Most drug tests are designed to detect unauthorized drug use. Methadone testing in the context of opioid treatment programs flips this: the point is often to confirm that the patient is actually taking the methadone they are being prescribed, rather than diverting it (selling it or giving it away). This is compliance monitoring, and it creates its own set of challenges.

A patient who is prescribed methadone but not taking it would test negative for both methadone and EDDP. A patient who takes the drug shortly before the test to appear compliant might have detectable methadone but lower-than-expected EDDP, since EDDP levels reflect steady-state metabolism over time rather than a single recent dose. Clinicians experienced in methadone programs learn to look at the ratio of methadone to EDDP, the trend over repeated tests, and the patient’s clinical presentation rather than relying on a single binary result.

Genetic variation in metabolism complicates this picture, as discussed above. A slow metabolizer on a stable dose will naturally produce less EDDP relative to methadone, and this can look superficially like non-compliance or recent “loading” of a missed dose. Programs that use both parent drug and metabolite testing together, rather than EDDP alone, are better positioned to distinguish genuine metabolic variation from diversion. The stakes are real: a false accusation of diversion can lead to discharge from a treatment program, which for someone with opioid use disorder can be life-threatening.

Understanding what methadone shows up as on a drug test is ultimately about understanding which test was ordered, what cutoff it uses, and what specimen it is analyzing. The drug has its own lane in the testing world, and knowing that it sits outside the standard opiate panel is the single most important fact for anyone navigating methadone treatment, employment screening, or forensic testing.